Europe Orders 110,000 Monkeypox Vaccines

Denmark-Based Bavarian Nordic A/S recently announced that the European Health Emergency Preparedness and Response Authority (HERA) had ordered 110,000 doses of Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) smallpox/monkeypox vaccines.

Known as Jynneos® in the USA, these vaccines will be made immediately available to E.U. Member States, Norway, and Iceland in response to the current monkeypox outbreak.

Deliveries of MVA-BN will be completed during the following months, stated the company on June 14, 2022.

Paul Chaplin, President and CEO of Bavarian Nordic, commented in a related press release, "We are pleased to enter an agreement with HERA on supplying our vaccine, thus helping to improve the E.U. readiness and response during the current outbreak of monkeypox throughout Europe."

"...while we have already delivered significant quantities of our vaccine to some individual E.U. member states, the supply to HERA now enables a more integrated and coordinated approach across the entire E.U., in line with HERA's mission."

MVA-BN is marketed as IMVANEX® in Europe and IMVAMUNE® in Canada and is a non-replicating vaccine developed in collaboration with the U.S. government.

Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to several undisclosed countries globally as part of their national biological preparedness.

As of June 16, 2022, about (48) countries have reported over 1,900 probable monkeypox patients.

As a result, most countries offer MVA-BN vaccines to the close-contacts and healthcare staff.

Additional monkeypox outbreak news is posted at Vax-Before-Travel.com/Monkeypox.

Note: The company's press release was manually curated for mobile readership.